Literature DB >> 19910416

Functional chimera of porcine pepsin prosegment and Plasmodium falciparum plasmepsin II.

Charity L Parr-Vasquez1, Rickey Y Yada.   

Abstract

Proplasmepsin II (zPMII) represents a unique member of the aspartic proteinase family, with a prosegment-enzyme interaction that is thus far unique among the pepsin-like proteases. The role of the prosegment in aspartic proteinase structure and function was investigated by generating two chimeric proteins, one with the pepsinogen prosegment fused to the mature region of PMII (pepproPMII) and a second with the prosegment of PMII fused to pepsin (PMIIpropep). Both chimeras were expressed using Escherichia coli; however, PMIIpropep was extremely unstable suggesting protein misfolding. Alternatively, pepproPMII was capable of both autoactivation and hydrolysis of a synthetic substrate. Similarly, when the PMII enzyme was expressed without a prosegment, it too exhibited activity against the synthetic enzyme. CD measurements indicated that pepproPMII had reduced thermal stability when compared with zPMII. This reduction of temperature stability may have resulted from the inability of the pepsinogen prosegment to stabilize the C-terminal domain of the PMII enzyme. The ability of PMII to fold in the presence of a completely non-homologous prosegment and in its absence suggests that prosegment is not critical to obtaining a functional enzyme in all pepsin-like enzymes but likely plays a role in protein stabilization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19910416     DOI: 10.1093/protein/gzp066

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  1 in total

1.  Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins - biochemical and structural insights.

Authors:  Vandana Mishra; Ishan Rathore; Anagha Arekar; Lakshmi Kavitha Sthanam; Huogen Xiao; Yoshiaki Kiso; Shamik Sen; Swati Patankar; Alla Gustchina; Koushi Hidaka; Alexander Wlodawer; Rickey Y Yada; Prasenjit Bhaumik
Journal:  FEBS J       Date:  2018-07-07       Impact factor: 5.542

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.